Literature DB >> 24598374

Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital.

Fatima Caracuel1, Nuria Muñoz2, Ursula Baños2, Gabriel Ramirez2.   

Abstract

PURPOSE: The aim of the study was to determine the antiemetic prescription adherence both to the protocol of our hospital and to international recommendations, as well as to analyze the relationship between this adherence and the incidence of nausea and vomiting (NV) and between the adherence and patients' individual risk.
METHODS: This is a four-month observational study which included antiemetic prescriptions for adult cancer patients. Prescriptions were considered adherent or not to hospital protocol and also to international guidelines. Patients were given a form to record the NV they suffered and this was to be returned at their next appointment.
RESULTS: A total of 102 prescriptions were analyzed. Taking into account the hospital protocol, 59% and 54% were correct (acute and delayed phase, respectively). Of those considered outside the protocol, 24% and 13% did follow international guidelines. In the delayed phase, complete response was achieved in 76% and 72% of the patients, with compliant and non-compliant prescriptions, respectively (82% and 90% in the acute phase). Adherence to the hospital protocol was higher in patients under 50 years old (p = 0.015) and in those without previous experience of NV (p = 0.010). Adherence to international guidelines was higher in female patients (p = 0.023).
CONCLUSION: Our study confirms low adherence with both local and international recommendations for antiemetic prescriptions. However, we could not prove that adherence involves a CINV reduction. Adherence did not seem to be influenced by the doctor's perception of the patient's risk of emesis.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Antiemetics; CINV; adherence; guidelines; prescription; protocols

Mesh:

Substances:

Year:  2014        PMID: 24598374     DOI: 10.1177/1078155214524809

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  9 in total

1.  A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Authors:  Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons
Journal:  Support Care Cancer       Date:  2017-03-09       Impact factor: 3.603

Review 2.  Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).

Authors:  Noha Rashad; Omar Abdel-Rahman
Journal:  Drug Des Devel Ther       Date:  2017-03-24       Impact factor: 4.162

3.  Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China.

Authors:  Xianglong Zong; Jie Zhang; Xin Ji; Jie Gao; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

4.  Control of chemotherapy-induced nausea and vomiting in patients with gastrointestinal tumours.

Authors:  Rok Barle; Tomaž Vovk; Borut Štabuc; Matej Dobravc Verbič
Journal:  Eur J Hosp Pharm       Date:  2016-06-21

5.  Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome.

Authors:  Masahiro Inoue; Manabu Shoji; Naomi Shindo; Kazunori Otsuka; Masatomo Miura; Hiroyuki Shibata
Journal:  BMC Pharmacol Toxicol       Date:  2015-03-28       Impact factor: 2.483

6.  Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.

Authors:  Myung Ah Lee; Eun Kyung Cho; Sung Yong Oh; Joong Bae Ahn; Ji Yun Lee; Burke Thomas; Hun Jung; Jong Gwang Kim
Journal:  Cancer Res Treat       Date:  2016-02-12       Impact factor: 4.679

7.  Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline.

Authors:  Vijay Patil; Vanita Noronha; Amit Joshi; Purvish Parikh; Atanu Bhattacharjee; Santam Chakraborty; Sunny Jandyal; Vamshi Muddu; Anant Ramaswamy; K Govinda Babu; Nilesh Lokeshwar; Sachin Hingmire; Nikhil Ghadyalpatil; Shripad Banavali; Kumar Prabhash
Journal:  J Glob Oncol       Date:  2016-11-09

Review 8.  Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.

Authors:  Rudolph M Navari; Lee S Schwartzberg
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

9.  Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.

Authors:  Y Escobar Álvarez; J De Castro Carpeño; D Bell; A Drago; A Franceschetti
Journal:  Clin Transl Oncol       Date:  2021-05-06       Impact factor: 3.405

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.